Literature DB >> 28687924

Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma.

Waqar Haque1, Vivek Verma2, E Brian Butler3, Bin S Teh4.   

Abstract

The standard of care for glioblastoma (GBM) is maximal safe resection followed by concurrent chemoradiation (CRT). For several neoplasms, receipt of radiation treatment at high-volume facilities has been associated with improved overall survival (OS). The purpose of the present investigation was to determine if there was an association between receipt of CRT for GBM at facilities with a higher case volume and improved OS. The National Cancer Data Base was queried for patients with GBM diagnosed between 2006 and 2012 that received full-course CRT. Statistics included Kaplan-Meier analysis to compare OS between patients treated facilities with the highest quartile volume (HVF) to those treated at lower case volume facilities, multivariate logistic regression to determine factors associated with treatment at a HVF, and Cox proportional hazards modeling to determine variables associated with OS. A total of 4892 patients met the specified criteria. Fourteen facilities (9.9%) treated the highest quartile volume of patients, while 69 (48.6%) treated the lowest quartile volume (LVF) of patients. Treatment at the HVF was associated with improved median OS (16.5 vs. 14.1 months, p < 0.001). Treatment at a LVF also independently predicted for worse OS on multivariate analysis, along with age >70 years, and a resection limited to a biopsy. This is the first study to demonstrate that treatment of GBM with CRT at a HVF is associated with improved survival. Major goals of future oncologic care should be to achieve greater standardization of quality of treatment across facilities with different case volumes.

Entities:  

Keywords:  Chemotherapy; Glioblastoma; Radiation therapy; Survival

Mesh:

Year:  2017        PMID: 28687924     DOI: 10.1007/s11060-017-2563-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.

Authors:  Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan
Journal:  J Neurooncol       Date:  2007-05-26       Impact factor: 4.130

2.  Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States.

Authors:  Lauren Gratian; John Pura; Michaela Dinan; Shelby Reed; Randall Scheri; Sanziana Roman; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2014-07-29       Impact factor: 5.344

3.  Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer.

Authors:  Amy Y Chen; Stacey Fedewa; Alex Pavluck; Elizabeth M Ward
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

4.  Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base.

Authors:  Waqar Haque; Vivek Verma; Mohamad Fakhreddine; Sandra Hatch; E Brian Butler; Bin S Teh
Journal:  Gynecol Oncol       Date:  2016-10-23       Impact factor: 5.482

5.  Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.

Authors:  Yu-Wei Chen; Brandon A Mahal; Vinayak Muralidhar; Michelle Nezolosky; Clair J Beard; Robert B Den; Felix Y Feng; Karen E Hoffman; Neil E Martin; Peter F Orio; Paul L Nguyen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-14       Impact factor: 7.038

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors:  Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  14 in total

1.  Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data.

Authors:  Alessandro Boaro; Vasileios K Kavouridis; Francesca Siddi; Elisabetta Mezzalira; Maya Harary; J Bryan Iorgulescu; David A Reardon; Timothy R Smith
Journal:  Acta Neurochir (Wien)       Date:  2021-04-19       Impact factor: 2.216

2.  Clinical benefit of treatment for metastatic renal cell cancer at high volume facilities.

Authors:  Waqar Haque; Monty Aghazadeh; Brian J Miles; Raj Satkunasivam; E Brian Butler; Bin S Teh
Journal:  Ann Transl Med       Date:  2018-12

3.  Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer.

Authors:  Vivek Verma; Pamela K Allen; Charles B Simone; Hiram A Gay; Steven H Lin
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-01-01       Impact factor: 6.223

4.  The impact of traveling distance and hospital volume on post-surgical outcomes for patients with glioblastoma.

Authors:  Christian Lopez Ramos; Michael G Brandel; Jeffrey A Steinberg; Arvin R Wali; Robert C Rennert; David R Santiago-Dieppa; Reith R Sarkar; J Scott Pannell; James D Murphy; Alexander A Khalessi
Journal:  J Neurooncol       Date:  2018-11-20       Impact factor: 4.130

5.  Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-10-31       Impact factor: 4.130

6.  Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Authors:  Jonathan B Lamano; Jason Balquidera Lamano; Yuping D Li; Joseph D DiDomenico; Winward Choy; Dorina Veliceasa; Daniel E Oyon; Shayan Fakurnejad; Leonel Ampie; Kartik Kesavabhotla; Rajwant Kaur; Gurvinder Kaur; Dauren Biyashev; Dusten J Unruh; Craig M Horbinski; C David James; Andrew T Parsa; Orin Bloch
Journal:  Clin Cancer Res       Date:  2019-03-01       Impact factor: 12.531

7.  Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-02

8.  Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-04

9.  Utilization of intensity modulated radiation therapy for anal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-06

10.  Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.

Authors:  Vivek Verma; Adams Kusi Appiah; Tim Lautenschlaeger; Sebastian Adeberg; Charles B Simone; Chi Lin
Journal:  J Gastrointest Oncol       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.